Double transplant breakthrough offers hope for rare immune disorder patients

NCT ID NCT01852370

ENROLLING_BY_INVITATION Disease control Sponsor: Paul Szabolcs Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people aged 5 to 45 with primary immune deficiencies and end-stage lung disease. Participants receive a double lung transplant followed by a stem cell transplant from the same donor. The goal is to see if this combined procedure is safe and can help the body accept the new lungs without needing lifelong anti-rejection drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE (CGD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic granulomatous disease common variable immunodeficiency DiGeorge syndrome hyper-IgE syndrome hyper-IgM syndrome inherited susceptibility to mycobacterial diseases Job Syndrome monocytopenia with susceptibility to infections neutropenia, chronic familial Omenn syndrome severe combined immunodeficiency severe congenital neutropenia T-cell immunodeficiency Wiskott-Aldrich syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRANULOMATOUS DISEASE (CGD) COMMON VARIABLE IMMUNE DEFICIENCY (CVID) HYPER IGE SYNDROMES HYPER IGM DEFICIENCIES IMMUNODEFICIENCY WITH PREDOMINANT T-CELL DEFECT, UNSPECIFIED MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE SEVERE CHRONIC NEUTROPENIA SEVERE COMBINED IMMUNODEFICIENCY (SCID) WISKOTT-ALDRICH SYNDROME

Contacts and locations

Locations

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.